![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TAKEDA ENDS JOINT NORTH AMERICAN SALE OF DIABETIC DRUG
TAKEDA ENDS JOINT NORTH AMERICAN SALE OF DIABETIC DRUG
April 24, 2006
Takeda Pharmaceutical Co. has put an end to its joint marketing with U.S. drug maker Eli Lilly & Co. of diabetic drug ACTOS in North America. Takeda Pharmaceuticals North America Inc. and Eli Lilly have jointly promoted sales of the drug in the target region since the product''s launch in 1999.
Mainichi Daily News (http://mdn.mainichi-msn.co.jp/business/news/20060424p2g00m0bu057000c.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct